Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:59

Review

Kukreja, Rakesh C.¹  Salloum, Fadi N.¹  Das, Anindita¹ 

[1] Virginia Commonwealth Univ, Pauley Heart Ctr, Div Cardiol, Dept Internal Med, Richmond, VA 23298 USA

关键词: cGMP;    cardiomyocytes;    infarction;    ischemia;    signaling;   

DOI  :  10.1016/j.jacc.2011.09.086

来源: Elsevier

【 摘 要 】

Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit. (J Am Coll Cardiol 2012; 59: 1921-7) (C) 2012 by the American College of Cardiology Foundation

【 授权许可】

Free